Epizyme Company Profile (NASDAQ:EPZM)

About Epizyme (EPZM)

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPZM
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $17.15
  • 50 Day Moving Average: $14.25
  • 200 Day Moving Average: $11.27
  • 52-Week Range: $7.02 - $17.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.52
  • P/E Growth: 0.00
  • Market Cap: $998.95M
  • Outstanding Shares: 58,248,000
  • Beta: 2.24
  • Net Margins: -1,205.01%
  • Return on Equity: -41.56%
  • Return on Assets: -34.78%
  • Current Ratio: 17.35%
  • Quick Ratio: 17.35%

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.83 (38.97% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/11/2017Royal Bank of CanadaReiterated RatingOutperform$26.00 -> $19.00N/AView Rating Details
11/28/2016WedbushReiterated RatingOutperform$22.00N/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
11/6/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
6/20/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
4/5/2016Citigroup IncInitiated CoverageBuy$17.00N/AView Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
(Data available from 3/25/2015 forward)


Earnings History for Epizyme (NASDAQ:EPZM)
Earnings by Quarter for Epizyme (NASDAQ:EPZM)
Earnings History by Quarter for Epizyme (NASDAQ:EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017Q4 2016($0.65)($0.60)ViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$6.60 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)ViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)ViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)ViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$5.42 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.45 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$5.63 millionViewN/AView Earnings Details
3/12/2015Q414($0.53)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.55)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.50)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.22)$8.48 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Epizyme (NASDAQ:EPZM)
Current Year EPS Consensus Estimate: $-2.55 EPS
Next Year EPS Consensus Estimate: $-2.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.63)($0.42)($0.51)
Q2 20164($0.68)($0.45)($0.55)
Q3 20163($0.64)($0.50)($0.57)
Q4 20163($0.73)($0.55)($0.63)
Q1 20173($0.65)($0.63)($0.64)
Q2 20172($0.67)($0.64)($0.66)
Q3 20173($0.69)($0.64)($0.66)
Q4 20173($0.71)($0.65)($0.67)
(Data provided by Zacks Investment Research)


Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Epizyme (NASDAQ:EPZM)
Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 79.98%
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.52View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.39View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.20View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Epizyme (NASDAQ:EPZM)
Latest Headlines for Epizyme (NASDAQ:EPZM)
americanbankingnews.com logoEpizyme Inc (EPZM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 23 at 11:50 AM
finance.yahoo.com logoEPIZYME, INC. Financials
finance.yahoo.com - March 16 at 6:21 PM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 11:54 AM
zacks.com logoEpizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
www.zacks.com - March 10 at 11:30 AM
finance.yahoo.com logoEdited Transcript of EPZM earnings conference call or presentation 9-Mar-17 1:30pm GMT
finance.yahoo.com - March 10 at 11:30 AM
seekingalpha.com logoEpizyme's (EPZM) CEO Robert Bazemore on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 5:31 PM
us.rd.yahoo.com logoEpizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
us.rd.yahoo.com - March 9 at 5:31 PM
us.rd.yahoo.com logo6:31 am Epizyme announces that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., will be retiring from the co in 2Q17 to pursue advisory and other opportunities within the industry
us.rd.yahoo.com - March 9 at 5:31 PM
us.rd.yahoo.com logoEpizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
us.rd.yahoo.com - March 9 at 5:31 PM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 9 at 5:31 PM
biz.yahoo.com logoQ4 2016 Epizyme Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 5:31 PM
biz.yahoo.com logoEpizyme Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 9 at 5:31 PM
finance.yahoo.com logoEpizyme (EPZM) Reports A Narrower Q4 Loss
finance.yahoo.com - March 9 at 5:31 PM
finance.yahoo.com logoEpizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences
finance.yahoo.com - March 7 at 11:45 AM
finance.yahoo.com logoCan Epizyme (EPZM) Spring a Surprise This Earnings Season?
finance.yahoo.com - March 7 at 11:45 AM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - February 8 at 5:32 PM
streetinsider.com logoEpizyme (EPZM) Elects Kevin Conroy to Board of Directors
www.streetinsider.com - February 7 at 6:11 PM
finance.yahoo.com logoEpizyme Elects Kevin Conroy to its Board of Directors
finance.yahoo.com - February 7 at 6:11 PM
globenewswire.com logoEpizyme to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 2 at 10:33 PM
finance.yahoo.com logoEpizyme to Present at Upcoming Investor Conferences
finance.yahoo.com - February 2 at 5:31 PM
finance.yahoo.com logoTherapeuticsMD's Rejoice Study Data Published in Journal
finance.yahoo.com - January 12 at 5:29 PM
finance.yahoo.com logoAlexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
finance.yahoo.com - January 11 at 5:35 PM
bizjournals.com logoNew England Venture Capital Association adds new board members
www.bizjournals.com - January 10 at 5:56 PM
zacks.com logoPuma (PBYI) Expands Study Cohort for Lead Candidate PB272
www.zacks.com - January 9 at 5:49 PM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - January 9 at 5:49 PM
globenewswire.com logoEpizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 3 at 7:05 PM
finance.yahoo.com logoEpizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
finance.yahoo.com - January 3 at 12:17 PM
finance.yahoo.com logoMoving Average Crossover Alert: Epizyme (EPZM)
finance.yahoo.com - December 20 at 10:02 AM


Frequently Asked Questions for Epizyme (NASDAQ:EPZM)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings results on Thursday, March, 9th. The company reported ($0.60) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.05. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%.

When will Epizyme make its next earnings announcement?

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?

8 equities research analysts have issued 12-month target prices for Epizyme's stock. Their predictions range from $17.00 to $39.00. On average, they anticipate Epizyme's stock price to reach $23.83 in the next twelve months.

Who owns Epizyme stock?

Epizyme's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.08%), Palo Alto Investors LLC (5.23%), Deerfield Management Co. (2.76%), Foresite Capital Management II LLC (2.63%), Franklin Resources Inc. (2.00%) and State Street Corp (1.88%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould.

Who sold Epizyme stock? Who is selling Epizyme stock?

Epizyme's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Foresite Capital Management II LLC and Foresite Capital Management III LLC. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer and Robert A Copeland.

Who bought Epizyme stock? Who is buying Epizyme stock?

Epizyme's stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., Norges Bank, State Street Corp, Palo Alto Investors LLC, J. Goldman & Co LP, Russell Investments Group Ltd., Dimensional Fund Advisors LP and Metropolitan Life Insurance Co. NY. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho.

How do I buy Epizyme stock?

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Epizyme stock cost?

One share of Epizyme stock can currently be purchased for approximately $17.15.

Epizyme (EPZM) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff